ASX-listed health technology company CardieX has announced that it has acquired Silicon Valley-based Blumio, a cardiovascular sensor algorithm developer and data analytics toolset.
CardieX focuses on hypertension, cardiovascular health and other arterial health disorders, while Blumio develops wearable sensor technologies aimed at capturing cardiovascular data, including blood pressure measurements.
The acquisition follows a three-year collaboration between the companies, which found Blumio’s sensor technology to be compatible with ATCOR’s CardieX subsidiary. SphygmoCor arterial technology that measures the central aortic pressure waveform.
CardieX will also use the Blumia funds to enhance its Arty Heart Health Analytics platform in its CONNEQT Pulse and for its CONNEQT Band devices.
“Blumio brings a suite of capabilities in wearable sensor development, signal processing and expertise in big data analytics that will benefit both our ATCOR and CONNEQT brands, especially in relation to ongoing development activities around our CONNEQT Band. This acquisition is a natural extension of our core solutions that provide a comprehensive ecosystem of unique health and wellness features focused on heart health,” CardieX Group CEO Craig Cooper said in a statement.
A BIGGER TREND
CardieX adds Blumio to its group of companies with many patented health technologies.
In March, CardieX and AI wearables company Mobvoi announced the launch of their TicWatch GTH Pro, which uses aspects of ATCOR’s SphygmoCor technology to monitor heart health.